Givinostat: an emerging treatment for polycythemia vera.

ABSTRACT:

Introduction

Polycythemia vera (PV), a Philadelphia chromosome-negative myeloproliferative neoplasm, is characterized by panmyelosis, pancytosis, and a JAK2 mutation. Patients are at increased risk of thrombohemorrhagic events, and progression to myelofibrosis or acute leukemia. Current treatments include aspirin, phlebotomy, and cytoreductive drugs (most commonly hydroxyurea). Givinostat is a potent, class I/II histone deacetylase (HDAC) inhibitor that is in phase I/II clinical trials in PV. Givinostat was well tolerated and yielded promising clinico-hematological responses. A phase III study of givinostat versus hydroxyurea in high-risk PV patients is planned.

Areas covered

We present an overview of PV, current treatment guidelines, and the putative mechanism(s) of

SUBMITTER: Chifotides HT 

PROVIDER: S-EPMC7534842 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature